SGHT
Sight Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.35
−0.36%Year over year
Reported trailing growth
- Revenue
- +9.3%
- EBITDA
- +40.5%
- EBIT
- +42.7%
- EPS
- +41.8%
- Free cash flow
- -4.1%
- Operating cash flow
- -5.6%
Forward estimates
Based on analyst estimates
- Revenue
- +14.8%
- EBITDA
- -28.4%
- EPS
- -15.8%
Three-year CAGR
- Revenue
- +2.7%
- EBITDA
- +28.6%
- EBIT
- +26.6%
- Net income
- +25.4%
- EPS
- +28.2%
- Free cash flow
- -31.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026